Promontory Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Promontory Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Promontory Therapeutics: 3 sponsored US clinical trials, none currently recruiting.
Promontory Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is PT-112, with 1 trials.
Upper-quartile sponsor footprint
Promontory Therapeutics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
NCT02266745
A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
NCT03409458
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
NCT03288480
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Therapeutic Areas
How the Promontory Therapeutics early-phase archive is shaped
3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: PT-112 (1 trial), 8 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Promontory Therapeutics: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Promontory Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Promontory Therapeutics page
3 registered trials is a research-attention snapshot, not an endorsement of Promontory Therapeutics or any single study.
- None of Promontory Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- PT-112 is the condition Promontory Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PT-112 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Promontory Therapeutics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.